Komori
Dividends4886ASKA Pharmaceutical Holdings Co.,Ltd.Pharmaceuticals

Notice Regarding Dividend of Surplus (Increase in Dividend) and Change in Dividend Policy

The year-end dividend for the fiscal year ending March 2026 is scheduled to increase to ¥33 per share from the previously forecast ¥28, raising the annual dividend from ¥55 to ¥60. In addition, from the fiscal year ending March 2027 onward, the Company will adopt a progressive dividend policy, targeting a total payout ratio of 40% and generally not reducing dividends, excluding special dividends.

Worth reading
70In focus
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Improvement
Direction inferred from the company’s description.
Scale
5
¥ per share
Wording
Conditional
How definitive the wording is.

Dividend per share

Fiscal year ending March 2026
60YenRevised annual dividend per sharePrevious forecast ¥55, change ¥+5(+9.1%)
Previous-period resultsPrevious forecastAfter revision

Each vertical step represents one dividend payment, and the total height of the accumulated steps represents the annual dividend for the period. For periods showing only the annual amount, the payment breakdown is not provided, so only the end point is plotted.

Dividend per share¥¥28→¥33+17.9%
Total dividendsTotal amount payable to all shareholders¥850 million→¥937 million
Whether Submission to the General Meeting of Shareholders Is RequiredScheduled to be submitted to the General Meeting of Shareholders
Record date31 March 2026
Effective date25 June 2026

The record date is the cutoff date for determining which persons listed in the shareholder register on that date are entitled to receive dividends.Payments begin on the effective date.

Payout ratioCurrent 31.4% (consolidated) / Policy Targeting a consolidated dividend payout ratio of 30% (before the change)The percentage of earnings paid out as dividends.
Source of dividendsRetained earningsThe source of dividend payments. Depending on the type of surplus, the dividend may be paid from earned profits or may be closer to a return of capital.
Dividend policy

Following the change, the Company will provide shareholder returns as a performance-linked profit distribution, targeting a total payout ratio of 40%, and aims to increase dividend levels in line with earnings growth. It will introduce a progressive dividend policy, excluding special dividends, and generally will not reduce dividends.

Dividend per share
ItemDetails
Dividend per share¥28 → ¥33(+17.9%)
Total Annual Dividends¥55 → ¥60(+9.1%)
Previous-period results (per share)Interim ¥25 / End of period ¥30 / Annual ¥55
Total dividends¥850 million → ¥937 million
Record date31 March 2026
Effective date25 June 2026
Source of dividendsRetained earnings
Payout ratioCurrent 31.4% (consolidated) / Policy Targeting a consolidated dividend payout ratio of 30% (before the change)
Dividend policyFollowing the change, the Company will provide shareholder returns as a performance-linked profit distribution, targeting a total payout ratio of 40%, and aims to increase dividend levels in line with earnings growth. It will introduce a progressive dividend policy, excluding special dividends, and generally will not reduce dividends.
Whether Submission to the General Meeting of Shareholders Is RequiredScheduled to be submitted to the General Meeting of Shareholders
Fiscal Period CoveredFiscal year ending March 2026
Items this document does not state (1)
Breakdown of Regular, Commemorative and Special Dividends

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

The changes are intended to further enhance shareholder returns and improve dividend stability and predictability. Based on the previous policy of targeting a consolidated dividend payout ratio of 30%, the Company plans to pay a year-end dividend of ¥33 per share for the current fiscal year and, from the fiscal year ending March 2027, will also consider flexible share repurchases while targeting a total payout ratio of 40%.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice Regarding Dividend of Surplus (Increase in Dividend) and Change in Dividend Policy | ASKA Pharmaceutical Holdings Co.,Ltd. (4886) timely disclosure | Komori